Comparison of prognostic factors in patients diagnosed with endometrial cancer before and after COVID 19 pandemic: a retrospective study

Year 2022, Volume: 5 Issue: 1, 216 - 219, 17.01.2022

Ahmet Bilgi , Fazıl Avcı , Havva Hande Keser Şahin , Bayram Can , Abdül Hamid Güler , Mehmet Kulhan , Cetin Celik

https://doi.org/10.32322/jhsm.1017866

Abstract

Aim: We aimed to compare prognostic factors in patients diagnosed with endometrial cancer before and after COVID 19 (Coronavirus Disease 19) pandemic.
Material and Method: This study was conducted in the Department of Gynecologic Oncology at Selçuk University Faculty of Medicine. After the World Health Organization (WHO) announced the COVID 19 pandemic on March 11, 2020, the Ministry of Health of the Republic of Turkey made an urgent decision on health services. The surgical cases diagnosed with endometrial cancer were divided into two groups based on the date when the pandemic was announced on March 11, 2020 and described group 1: 19 months before the pandemic, group 2: 19 months after the pandemic. Demographics, prognostic variables (stage, histologic type, grade, myometrial invasion, lymphovascular invasion, stromal involvement, and tumor size), endometrial cancer histological types, and treatment phases were all statistically assessed (early stage, advanced stage).
Results: A total of 194 cases were included, 96 cases in the first group and 98 cases in the second group. The mean age of the first group was 60.9±9.8 (40-86) years, the second group was 60.9±9.4 (36-82) years. There was statistically significant difference in clinicopathologic of endometrial cancer between group 1 and group 2, histologic type and grade (p=0.02; p=0.009 and p=0.018, respectively). There was no statistical difference between the two groups in age, stage, lymphatic and vascular space infiltration, muscular layer infiltration, interstitial infiltration and tumor size.
Conclusion: In the post-COVID 19 pandemic, more detection of type 2 of endometrial cancer, poor histological type and high grade, which have bad prognostic factors are found to be which may be due to the early admission of extra genital complaints. More randomized multicenter studies are needed on this subject.

Keywords

Covid 19 pandemia, endometrial cancer, prognostic factors

References

• Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry 2020; 7: 611-27. 
• Calabrò L, Peters S, Soria JC, et al. Challenges in lung cancer therapy during the COVID-19 pandemic. Lancet Respir Med 2020; 8: 542-4.
• Ministry of Health. Türkiye Republic Ministry of Health Corona Table (Internet). Available at: https://covid19.saglik.gov.tr. Accessed Apr 01.
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506.
• World Health Organization. Novel coronavirus (COVID-19) situation (Internet). Available at: https://www.who.int/emergencies/diseases/novel-coronavirus- 2019. Accessed Apr 16.
• Akladios C, Azais H, Ballester M, et al. Recommendations for the surgical management of gynecological cancers during the COVID-19 pandemic - FRANCOGYN group for the CNGOF. J Gynecol Obstet Hum Reprod 2020; 49: 101729.
• COVID 19: Elective Case Triage Guidelines for Surgical Care, College of American Surgeons 2020 (Available from: https://www.facs.org/covid-19/clinical- guidance/elective-case.
• Surgical Considerations for Gynecologic Oncologists During the COVID-19 Pandemic, Society of Gynecologic Oncology 2020.
• Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21: 335-7.
• Cortiula F, Pettke A, Bartoletti M, Puglisi F, Helleday T. Managing COVID-19 in the oncology clinic and avoiding the distraction effect. Ann Oncol 2020; 31: 553-5.
• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90. 
• Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer 2016; 26: 2-30.
• Wright JD, Lewin SN, Barrena Medel NI, et al. Endometrial cancer in the oldest old: Tumor characteristics, patterns of care, and outcome. Gynecol Oncol 2011; 122: 69-74.
• Lachance JA, Everett EN, Greer B, et al. The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol 2006; 101: 470-5.
• American Cancer Society. Cancer Statistics for USA 2020. Available online: https://www.cancer.org/cancer/endometrialcancer/about/key-statistics.html (accessed on 4 November 2020).
• Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium (published correction appears in Int J Gynaecol Obstet 2010 Feb;108(2):176). Int J Gynaecol Obstet 2009; 105: 103-4.
• Kamboj M, Sepkowitz KA. Nosocomial infections in patients with cancer. Lancet Oncol 2009;10:589-97. 
• Longbottom ER, Torrance HD, Owen HC, et al. Features of postoperative ımmune suppression are reversible with ınterferon gamma and ındependent of ınterleukin-6 pathways. Ann Surg 2016; 264: 370-7.
• Sica A, Massarotti M. Myeloid suppressor cells in cancer and autoimmunity. J Autoimmun 2017; 85: 117-25. 
• Cancer Statistics Review,-.-S.S.,https://seer.cancer.gov/csr/1975_2018/ (accessed June 6, 2021).
• Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15: 10-7.
• Peungjesada S, Bhosale PR, Balachandran A, Iyer RB. Magnetic resonance imaging of endometrial carcinoma. J Comput Assist Tomogr 2009; 33: 601-8.
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115-32.
• Carlson JW, Nastic D. High-grade endometrial carcinomas: classification with molecular ınsights. Surg Pathol Clin 2019; 12: 343-62.
• Slomovitz BM, Burke TW, Eifel PJ, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 2003; 91: 463-9.
• Chaudhry P, Asselin E. Resistance to chemotherapy and hormone therapy in endometrial cancer. Endocr Relat Cancer 2009; 16: 363-80. 
• Dolly D, Mihai A, Rimel BJ, et al. A Delay from diagnosis to treatment is associated with a decreased overall survival for patients with endometrial cancer. Front Oncol 2016; 6: 31.